Neupro (Rotigotine Transdermal System) Drug Information: Description, User Reviews, Drug Side Effects, Interactions

Pill Identifier Search

May 27, 2012

Neupro

Parkinson's Disease »

What is Parkinson's disease?

Parkinson's disease is the second most common neurodegenerative disorder and the most common movement disorder. It is characterized by progressive loss of muscle control, which leads to trembling of the limbs and head while at rest, stiffness, slowness, and impaired balance. As symptoms worsen, it may become difficult to walk, talk, and complete simple tasks.

The progression of Parkinson's disease and the degree of impairment vary from individual to individual. Many people with Parkinson's disease live long productive lives, whereas others become disabled much more quickly. Premature death is usually due to complications such as falling-related injuries or pneumonia.

In the United States, about 1 million people are affected by Parkinson's disease and worldwide about 5 million. Most individuals who develop Parkinson's disease are 60 years of age or older. Parkinson's disease occurs in approximately 1% of i...

Read the Parkinson's Disease article »

« Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
Next »

Neupro User Reviews >>

Neupro

Parkinson's Disease Slideshow Pictures

Dementia Slideshow Pictures

Take the Parkinson's Quiz

font size

Please Note: This Brand Name drug is no longer available in the US.
(Generic versions may still be available.)

Neupro
(rotigotine transdermal system)

DRUG DESCRIPTION

Neupro is a transdermal system that provides continuous delivery of rotigotine, a non-ergoline dopamine agonist, for 24 hours following application to intact skin.

Neupro is available in six strengths as shown in Table 4.

Table 4 : Nominal Dose, Drug Content, and Transdermal System Size

Neupro Nominal Dose	Rotigotine Content per System	Neupro System Size
1 mg/24 hours	2.25 mg	5 cm²
2 mg/24 hours	4.5 mg	10 cm²
3 mg/24 hours	6.75 mg	15 cm²
4 mg/24 hours	9 mg	20 cm²
6 mg/24 hours	13.5 mg	30 cm²
8 mg/24 hours	18 mg	40 cm²

The chemical name of rotigotine is (6S)-6-{propyl[2-(2-thienyl)ethyl]amino}-5,6,7,8-tetrahydro-1-naphthalenol. The empirical formula is C₁₉H₂₅NOS. The molecular weight is 315.48. The structural formula for rotigotine is:.

Neupro (Rotigotine) Structural Formula Illustration

System Components and Structure

Neupro is a thin, matrix-type transdermal system composed of three layers as shown in Figure 1:

Figure 1: System Schematic

A flexible, tan-colored backing film, consisting of an aluminized polyester film coated with a pigment-layer on the outer side. The backing provides structural support and protection of the drug-loaded adhesive layer from the environment.

A self-adhesive drug matrix layer, consisting of the active component rotigotine and the following inactive components: ascorbyl palmitate, povidone, silicone adhesive, sodium metabisulfite, and dl-alpha-tocopherol.

A protective liner, consisting of a transparent fluoropolymer-coated polyester film. This liner protects the adhesive layer during storage and is removed just prior to application.

What are the possible side effects of rotigotine (Neupro)?

Get emergency medical help if you have any of these signs of an allergic reaction: hives; difficulty breathing; swelling of your face, lips, tongue, or throat.

Call your doctor at once if you have any of these serious side effects:

extreme drowsiness, falling asleep suddenly, even after feeling alert;
nausea, sweating, feeling light-headed, fainting;
breathing problems;
severe headache, blurred vision, trouble concentrating, chest pain, numbness, seizure;
hallucinations;

Read All Potential Side Effects and See Pictures of Neupro »